<p>Pharming Group（OTCMKTS:PHGUF - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（$0.01），據 Zacks 報道。Pharming Group 的股本回報率為 4.68%，淨利潤率為 3.30%。該公司本季度的收入為 7245 萬美元，而分析師預計為 9206 萬美元。</p>
<p>獲取 <strong>Pharming Group</strong> 警報：</p>
<h2>Pharming Group 股票表現</h2>
<p>週五中午交易時，Pharming Group 的股票價格保持在$1.25。該公司交易了 5,071 股股票，而其平均交易量為 390 股。Pharming Group 的股價一年低點為$0.96，一年高點為$2.17。該公司的市值為 8.3696 億美元，市盈率為 62.39，貝塔值為 0.55。該股票的 50 日移動平均線為$1.60，200 日移動平均線為$1.65。該公司的速動比率為 2.03，流動比率為 2.59，債務與股本比率為 0.39。</p>
<h2>Pharming Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Pharming Group NV 是一家總部位於荷蘭的生物製藥公司，專注於為罕見疾病開發和商業化蛋白質替代療法。公司成立於 1988 年，總部位於萊頓，利用轉基因技術生產重組蛋白，其旗艦產品 RUCONEST（重組 C1 酯酶抑制劑）用於治療急性遺傳性血管水腫（HAE）發作。RUCONEST 已在美國、歐洲及其他多個地區獲得批准並通過與領先的專業製藥公司合作進行市場推廣。</p>
<p>除了 RUCONEST，Pharming 還保持着多樣化的產品線，針對罕見和超罕見疾病的未滿足需求。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Pharming Group</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Pharming Group 嗎？</h2>
<p>在考慮 Pharming Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Pharming Group 並不在名單上。</p>
<p>雖然 Pharming Group 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PHAR

醫藥突破 ETF - ALPS

IBBQ

<p>Pharming Group (OTCMKTS:PHGUF) 發佈了季度財報，顯示每股收益虧損為 ($0.01)，收入為 7245 萬美元，低於分析師預期的 9206 萬美元。該公司的股本回報率為 4.68%，淨利潤率為 3.30%。Pharming 的股票保持在 1.25 美元，市值為 8.3696 億美元。該公司專注於罕見疾病的蛋白質替代療法，其主要產品 RUCONEST 已在多個地區獲得批准</p>

<p>Pharming Group (OTCMKTS:PHGUF - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.</p>
<div class="lb-trans"><p>Pharming Group（OTCMKTS:PHGUF - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益（EPS）為（$0.01），據 Zacks 報道。Pharming Group 的股本回報率為 4.68%，淨利潤率為 3.30%。該公司本季度的收入為 7245 萬美元，而分析師預計為 9206 萬美元。</p>
</div><p>Get <strong>Pharming Group</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pharming Group</strong> 警報：</p>
</div><h2>Pharming Group Stock Performance</h2>
<div class="lb-trans"><h2>Pharming Group 股票表現</h2>
</div><p>Shares of Pharming Group stock remained flat at $1.25 during mid-day trading on Friday. 5,071 shares of the company's stock traded hands, compared to its average volume of 390. Pharming Group has a one year low of $0.96 and a one year high of $2.17. The company has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.65. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39.</p>
<div class="lb-trans"><p>週五中午交易時，Pharming Group 的股票價格保持在$1.25。該公司交易了 5,071 股股票，而其平均交易量為 390 股。Pharming Group 的股價一年低點為$0.96，一年高點為$2.17。該公司的市值為 8.3696 億美元，市盈率為 62.39，貝塔值為 0.55。該股票的 50 日移動平均線為$1.60，200 日移動平均線為$1.65。該公司的速動比率為 2.03，流動比率為 2.59，債務與股本比率為 0.39。</p>
</div><h2>Pharming Group Company Profile</h2>
<div class="lb-trans"><h2>Pharming Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.</p>
<div class="lb-trans"><p>Pharming Group NV 是一家總部位於荷蘭的生物製藥公司，專注於為罕見疾病開發和商業化蛋白質替代療法。公司成立於 1988 年，總部位於萊頓，利用轉基因技術生產重組蛋白，其旗艦產品 RUCONEST（重組 C1 酯酶抑制劑）用於治療急性遺傳性血管水腫（HAE）發作。RUCONEST 已在美國、歐洲及其他多個地區獲得批准並通過與領先的專業製藥公司合作進行市場推廣。</p>
</div><p>Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.</p>
<div class="lb-trans"><p>除了 RUCONEST，Pharming 還保持着多樣化的產品線，針對罕見和超罕見疾病的未滿足需求。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Pharming Group</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Pharming Group</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVBIR1VG" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=OTCMKTS&amp;Symbol=PHGUF"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pharming Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Pharming Group 嗎？</h2>
</div><p>Before you consider Pharming Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Pharming Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户在更廣泛的市場注意到之前購買的股票……而 Pharming Group 並不在名單上。</p>
</div><p>While Pharming Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Pharming Group 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Pharming Group (OTCMKTS:PHGUF) 公佈季度財報結果